Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2026/27
Cision•29/10/2026•10:03 ET
1
Key Highlights
- ➤Q2 2026/27 interim report scheduled for publication on November 5, 2026
- ➤CEO Axel Schörling to present and comment on the interim report
- ➤EQL Pharma has 49 niche generics launched across Nordic markets
- ➤Additional niche generics pipeline targeted for launch in 2026 and beyond
Expert Statements
Axel Schörling, CEO and President of EQL Pharma AB
“CEO and President Axel Schörling presents and comments on the interim report.”
EQL Pharma EQL Pharma AB (publ) will publish its interim report for the second quarter, 2026/27, on Thursday, 5th November.
At 10.00 (CET) 5th November, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/3fynsvf9
Get started
Create a free account to read the full story.